

FOI3551

20th January 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Response:

Current numbers as of 08/01/2026

Name of biologic drug	Total number of patients
Adalimumab – Humira	29
Adalimumab Biosimilar	314
Apremilast	0
Bimekizumab	14
Brodalumab	5
Certolizumab	<5*
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept – Enbrel	0
Etanercept Biosimilar	<5*
Guselkumab	66
Infliximab – Remicade	0
Infliximab Biosimilar	10
Ixekizumab	123
Risankizumab	121
Secukinumab	50
Tildrakizumab	5
Ustekinumab – Stelara	<5*
Ustekinumab Biosimilar	22
Omalizumab	37
Spesolimab	0

* The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals

concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Response:

Current numbers as of 08/01/26

Name of biologic drug	Total number of patients
Adalimumab – Humira	20
Adalimumab Biosimilar	57
Bimekizumab	0
Certolizumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	7
Secukinumab	18
Ustekinumab – Stelara	0
Ustekinumab Biosimilar	0

Email: Foi.Team@Southerntrust.hscni.net